XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.3

Collaboration and License Agreements and Supply Agreements (Tables)

9 Months Ended

Sep. 30, 2023

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

In accordance with the collaboration agreements, the Company recognized revenue as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(in thousands)								(in thousands)
Bristol Myers Squibb Company (“BMS”)		$	189				4,343			$	5,591				8,774
Merck Sharp & Dohme Corporation (“Merck”)			83				10,157				2,776				11,367
Merck KGaA, Darmstadt, Germany (operating in the United    States and Canada under the name “EMD Serono”)			-				166				8				2,200
Astellas Pharma Inc. (“Astellas”)			9,988				4,985				23,593				4,985
Tasly Biopharmaceuticals Co., Ltd. (“Tasly”)			5,072				-				5,072				25,000
Vaxcyte			1,592				1,496				2,970				2,814
BioNova Pharmaceuticals, Ltd. (“BioNova”)			-				4,000				-				4,000
Total revenue		$	16,924			$	25,147			$	40,010				59,140

Summary of Deferred Revenue Balance

The following table presents the changes in the Company’s deferred revenue balance from collaboration agreements during the nine months ended September 30, 2023:

		Nine Months Ended
		September 30, 2023
		(in thousands)
Deferred revenue—December 31, 2022		$	106,644
Additions to deferred revenue			11,018
Recognition of revenue in current period			(15,525	)
Deferred revenue—September 30, 2023		$	102,137

2018 BMS Master Services Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the BMS Agreement and the 2018 BMS Master Services Agreement were as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(in thousands)								(in thousands)
Research and development services		$	-			$	107			$	413			$	591
Materials supply			189				4,236				5,178				8,183
Total revenue		$	189			$	4,343			$	5,591			$	8,774

2020 Merck Master Services Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the 2018 Merck Agreement and the 2020 Merck Master Services Agreement were as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(in thousands)								(in thousands)
Ongoing performance related to    unsatisfied performance obligations		$	-			$	-			$	-			$	862
Contingent payment			-				10,000				-				10,000
Research and development services			20				136				224				402
Materials supply			63				21				2,552				103
Total revenue		$	83			$	10,157			$	2,776			$	11,367

2019 EMD Serono Supply Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the EMD Serono agreements were as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(in thousands)								(in thousands)
Research and development services		$	-			$	78			$	6			$	494
Materials supply			-				88				2				1,706
Total revenue		$	-			$	166			$	8			$	2,200

Supply Agreement | Vaxcyte, Inc.

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the Vaxcyte Supply Agreement were as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(in thousands)								(in thousands)
Research and development services		$	636			$	651			$	1,707			$	1,794
Materials supply			956				845				1,263				1,020
Total revenue		$	1,592			$	1,496			$	2,970			$	2,814

Astellas License and Collaboration Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the Astellas Agreement were as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(in thousands)								(in thousands)
Ongoing performance related to    unsatisfied performance obligations		$	5,612			$	1,925			$	11,423			$	1,925
Research and development services			1,920				809				4,639				809
Financing component on unearned revenue			2,456				2,251				7,531				2,251
Total revenue		$	9,988			$	4,985			$	23,593			$	4,985

Tasly License Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the Tasly License Agreement were as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(in thousands)								(in thousands)
Upfront payment		$	–			$	–			$	–			$	25,000
Contingent payments			5,000				–				5,000				–
Research and development services			72				–				72				–
Total revenue		$	5,072			$	–			$	5,072			$	25,000

X

- Definition

Milestone method revenue recognition.

+ References

No definition available.

+ Details

Name:	stro_MilestoneMethodRevenueRecognitionTableTextBlock
Namespace Prefix:	stro_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=stro_TwoThousandEighteenBmsMasterServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=stro_TwoThousandTwentyMerckMasterServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=stro_TwoThousandNineteenEMDSeronoSupplyAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=stro_SupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=stro_VaxcyteIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=stro_AstellasLicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=stro_TaslyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: